Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial
published in: Lancet Oncology Commission
date of publication: 2015-08-10
main subject: phase III clinical trial, bevacizumab
Cites articles 44
- 2000-01
Date
Title
Article - wd:Q36219254